All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition

The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Lacutamab for advanced mycosis fungoides: Are the early results promising?

During the 16th International Conference on Malignant Lymphoma (16-ICML), the Lymphoma Hub spoke with Martine Bagot, Hôpital Saint-Louis, Paris, FR. We asked, Lacutamab for advanced mycosis fungoides: Are the early results promising?

Lacutamab for advanced mycosis fungoides: Are the early results promising?

Bagot outlines the encouraging results, presented at ICML, of the phase II2518 investigating lacutamab, an anti-KIR3DL2 cytotoxicity-inducing antibody. She reports a promising safety profile and overall survival with this treatment.

 

Share: